title: Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes.
abstract: Patients with altered skin immunity, such as individuals with atopic dermatitis (AD), can have a life-threatening disruption of the epidermis known as eczema vaccinatum after vaccinia virus (VV) infection of the skin. Here, we sought to better understand the mechanism(s) by which VV associates with keratinocytes. The class A scavenger receptor known as MARCO (macrophage receptor with collagenous structure) is expressed on human and mouse keratinocytes and found to be abundantly expressed in the skin of patients with AD. VV bound directly to MARCO, and overexpression of MARCO increased susceptibility to VV infection. Furthermore, ligands with affinity for MARCO, or excess soluble MARCO, competitively inhibited VV infection. These findings indicate that MARCO promotes VV infection and highlights potential new therapeutic strategies for prevention of VV infection in the skin.
authors.affiliation: Division of Dermatology, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
authors.forename: Daniel T
authors.initials: DT
authors.lastname: MacLeod
authors.affiliation: Division of Dermatology, Department of Medicine, University of California, San Diego, La Jolla, California, USA; Veterans Affairs San Diego Health Care System, San Diego, California, USA.
authors.forename: Teruaki
authors.initials: T
authors.lastname: Nakatsuji
authors.affiliation: Division of Dermatology, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
authors.forename: Zhenping
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Division of Dermatology, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: di Nardo
authors.affiliation: Division of Dermatology, Department of Medicine, University of California, San Diego, La Jolla, California, USA; Veterans Affairs San Diego Health Care System, San Diego, California, USA. Electronic address: rgallo@ucsd.edu.
authors.forename: Richard L
authors.initials: RL
authors.lastname: Gallo
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D003876:Dermatitis, Atopic / Q000209:etiology / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011485:Protein Binding / Q000276:immunology; D011971:Receptors, Immunologic / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D051116:Receptors, Scavenger / Q000037:antagonists & inhibitors / Q000378:metabolism; D012900:Smallpox Vaccine / Q000009:adverse effects* / Q000276:immunology; D014615:Vaccinia / Q000276:immunology* / Q000378:metabolism / Q000517:prevention & control; D014616:Vaccinia virus / Q000276:immunology* / Q000378:metabolism; D014765:Viral Vaccines
chemical_list: C490460:MARCO protein, human; C092228:Marco protein, mouse; D011971:Receptors, Immunologic; D051116:Receptors, Scavenger; D012900:Smallpox Vaccine; D014765:Viral Vaccines
references.citation: Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1541-7
references.pmid: 9763524
references.citation: J Gen Virol. 2005 May;86(Pt 5):1279-1290
references.pmid: 15831938
references.citation: Arch Virol. 1998;143(12):2371-80
references.pmid: 9930193
references.citation: Mol Pharm. 2009 Mar-Apr;6(2):366-74
references.pmid: 19227971
references.citation: Antiviral Res. 2003 Apr;58(2):101-14
references.pmid: 12742570
references.citation: Clin Infect Dis. 2003 Jul 15;37(2):241-50
references.pmid: 12856217
references.citation: J Virol. 1999 Oct;73(10):8750-61
references.pmid: 10482629
references.citation: Nat Med. 2009 Jul;15(7):798-801
references.pmid: 19543282
references.citation: Proc Natl Acad Sci U S A. 2010 May 18;107(20):9346-51
references.pmid: 20439710
references.citation: N Engl J Med. 2003 Jan 30;348(5):439-46
references.pmid: 12496351
references.citation: Parasitology. 2005;130 Suppl:S11-25
references.pmid: 16281988
references.citation: J Allergy Clin Immunol. 2007 Apr;119(4):1022-5
references.pmid: 17353034
references.citation: J Virol. 2000 Apr;74(7):3353-65
references.pmid: 10708453
references.citation: J Immunol. 2003 Sep 15;171(6):3154-62
references.pmid: 12960343
references.citation: N Engl J Med. 1987 Mar 12;316(11):673-6
references.pmid: 3821799
references.citation: Clin Infect Dis. 2003 Jul 15;37(2):251-71
references.pmid: 12856218
references.citation: Virology. 2009 Jun 20;389(1-2):132-40
references.pmid: 19428041
references.citation: Clin Infect Dis. 2008 May 15;46(10):1555-61
references.pmid: 18419490
references.citation: JAMA. 1970 Apr 20;212(3):441-4
references.pmid: 4392370
references.citation: Infect Disord Drug Targets. 2008 Sep;8(3):144-55
references.pmid: 18782031
references.citation: Virology. 1996 May 15;219(2):339-49
references.pmid: 8638399
references.citation: J Infect Dis. 2003 Aug 1;188(3):414-23
references.pmid: 12870123
references.citation: Br Med J. 1964 Oct 10;2(5414):906-8
references.pmid: 14185655
references.citation: Immunity. 2006 Mar;24(3):341-8
references.pmid: 16546102
references.citation: Clin Immunol. 2006 Dec;121(3):332-8
references.pmid: 17015038
references.citation: EMBO J. 2002 Oct 1;21(19):5017-25
references.pmid: 12356718
references.citation: J Allergy Clin Immunol. 2007 Feb;119(2):457-63
references.pmid: 17141855
references.citation: Mol Immunol. 2010 Jan;47(4):883-93
references.pmid: 19914718
references.citation: PLoS Pathog. 2009 Jun;5(6):e1000480
references.pmid: 19543380
references.citation: J Biol Chem. 1993 Mar 5;268(7):4569-72
references.pmid: 8383115
references.citation: Science. 2008 Apr 25;320(5875):531-5
references.pmid: 18436786
references.citation: J Clin Invest. 2007 Mar;117(3):803-11
references.pmid: 17290304
references.citation: Virology. 2009 Mar 15;385(2):368-82
references.pmid: 19162289
references.citation: Blood. 2011 Jan 27;117(4):1319-28
references.pmid: 21098741
references.citation: Nat Commun. 2013;4:1963
references.pmid: 23739639
references.citation: Nature. 1990 Feb 8;343(6258):531-5
references.pmid: 2300204
references.citation: J Invest Dermatol. 2007 Feb;127(2):331-41
references.pmid: 17068485
references.citation: J Immunol. 2012 Jan 1;188(1):345-57
references.pmid: 22140255
references.citation: J Biol Chem. 2006 May 5;281(18):12767-75
references.pmid: 16524885
references.citation: J Biol Chem. 1991 Jul 25;266(21):13712-8
references.pmid: 1856205
references.citation: Br J Dermatol. 1971 Feb;84(2):169-73
references.pmid: 4926866
references.citation: Nat Cell Biol. 2006 Aug;8(8):793-802
references.pmid: 16862146
references.citation: J Virol. 2012 May;86(10):5686-96
references.pmid: 22438546
references.citation: FASEB J. 2008 Jan;22(1):159-67
references.pmid: 17709607
references.citation: J Infect Dis. 1973 Sep;128(3):308-11
references.pmid: 4728690
references.citation: Immunology. 2005 Apr;114(4):531-41
references.pmid: 15804290
references.citation: PLoS Pathog. 2010 Mar 26;6(3):e1000829
references.pmid: 20360967
references.citation: Nature. 2001 Nov 22;414(6862):454-7
references.pmid: 11719807
references.citation: J Virol. 1998 Feb;72(2):1577-85
references.pmid: 9445060
references.citation: N Engl J Med. 1969 Nov 27;281(22):1220-4
references.pmid: 4186804
references.citation: Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6442-7
references.pmid: 20308556
references.citation: J Immunol. 2004 Feb 1;172(3):1763-7
references.pmid: 14734759
references.citation: Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17517-21
references.pmid: 19805093
references.citation: Vaccine. 2009 Feb 18;27(8):1154-65
references.pmid: 19146908
references.citation: J Virol. 2007 Mar;81(5):2149-57
references.pmid: 17166913